Alnylam Pharmaceuticals Enters Material Definitive Agreement
Ticker: ALNY · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1178670
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
Related Tickers: ALNY
TL;DR
Alnylam just signed a big deal, new financial obligation incoming.
AI Summary
On September 30, 2025, Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered at 675 West Kendall Street in Cambridge, MA, filed an 8-K report detailing this obligation.
Why It Matters
This filing indicates a new financial commitment or obligation for Alnylam Pharmaceuticals, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into new financial obligations can introduce financial risk, but the specific nature and terms of the agreement are not detailed in this initial filing.
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- 675 West Kendall Street (location) — Principal executive offices address
- Cambridge, MA (location) — Principal executive offices city and state
FAQ
What type of material definitive agreement did Alnylam Pharmaceuticals, Inc. enter into?
The filing states that Alnylam Pharmaceuticals, Inc. entered into a material definitive agreement, but does not specify the type of agreement.
What is the nature of the direct financial obligation created?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but does not provide specific details about the obligation itself.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 30, 2025.
Where are Alnylam Pharmaceuticals, Inc.'s principal executive offices located?
Alnylam Pharmaceuticals, Inc.'s principal executive offices are located at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142.
What is the SEC file number for Alnylam Pharmaceuticals, Inc.?
The SEC file number for Alnylam Pharmaceuticals, Inc. is 001-36407.
Filing Stats: 1,276 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2025-10-03 16:15:23
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share ALNY The Nasdaq
- $500.0 million — . The Credit Agreement provides for a $500.0 million revolving line of credit (the "Revolvin
- $150.0 million — evolving Credit Facility"), including a $150.0 million letter of credit sublimit. The Credit A
- $630.0 million — redit Agreement) exceeds the greater of $630.0 million and 100% of the Company's Consolidated
Filing Documents
- d19737d8k.htm (8-K) — 30KB
- d19737dex101.htm (EX-10.1) — 1040KB
- 0001193125-25-230201.txt ( ) — 1441KB
- alny-20250930.xsd (EX-101.SCH) — 3KB
- alny-20250930_lab.xml (EX-101.LAB) — 18KB
- alny-20250930_pre.xml (EX-101.PRE) — 11KB
- d19737d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Credit Agreement, dated September 30, 2025, among Alnylam Pharmaceuticals, Inc., the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer